An observational study in Coronary Disease, sponsored by Fondazione GISE Onlus. Status unknown at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-07-28.
Sponsored by Fondazione GISE Onlus · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Coronary Disease with a site in Italy — 10 open to participants now, 13 under way, none of them phase 3. Coronary Disease · Italy.
Among the 58 studies in Coronary Disease with a site in Italy, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2022, is one of 21 observational ones, and was the 41st registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →10 of the 58 studies in Coronary Disease with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 18+
Catholic University of the Sacred Heart · Sites in Italy
Ages 40–69 · Healthy volunteers
Robocath · Sites in Italy, Belgium, France and 3 more countries
Ages 18–120
Tampere University · Sites in Italy, Finland, Germany and 3 more countries
Ages 30–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is below the median of 916 across 478 observational studies indexed under Coronary Disease.
Median enrollment 476 across the 37 interventional studies, 1,000 across the 21 observational. Of the 34 that completed or were terminated, 12 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 58 have an industry lead sponsor. The 10 most frequent:
Fondazione GISE Onlus is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Fondazione GISE Onlus has 2 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04433052Tampere UniversityClinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD | 2026-12 |
| NCT01218776University of BolognaInternational Survey of Acute Coronary Syndromes | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 58 studies in Coronary Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of Efficacy/Safety in Cangrelor use in patients with SCAD undergoing complex PCI.
Prospective, observational, multicenter registry.
SCAD patients routinely in the Italian centers undergo complex PCIs with pre-treatment with P2Y12 inhibitors or with P2Y12 inhibitors administration after procedure. This implies that participants receive interventions as part of routine medical care, and that researchers actually observe the effect of the intervention.
Patients with SCAD undergoing complex PCI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient presenting with SCAD undergoing complex PCI and:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo: * Assessment of platelet reactivity (Time 0, T0) (VFN) * PCI (start = T1; end= T2)
SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo: * Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0) * Assessment of platelet reactivity (Time 0, T0) (VFN) * PCI (start of PCI= T1; end of infusion of Cangrelor= T2)
Safety endpoint: Major bleedings according with Thrombolysis in Myocardial Infarction (TIMI) classification.
Number of patients with intracranial hemorrhage or a ≥5 g/dl decrease in hemoglobin concentration or a ≥15 % absolute decrease in hematocrit.
Time frame: hour 48
Efficacy endpoint: Long-term major adverse cardiac and cerebrovascular events MACCE (eg Death from any cause, Any Myocardial infarction, Revascularization, Stroke)
Number of patients with Long-term major adverse cardiac and cerebrovascular events (MACCE) (e.g. Death from any cause, Any Myocardial infarction, Revascularization, Stroke)
Time frame: hour 48 and day 30
Assessment of platelet reactivity
Assessment of platelet reactivity measured by the VerifyNow® P2Y12 assay. Pharmacodynamic measurements will occur according to manufacturer instructions before, during, and after study drug infusion.
Time frame: Day 0
Number of Participants with stent thrombosis
Number of Participants with stent thrombosis demonstrated by coronary angiography
Time frame: hour 48
Rehospitalisation due to unstable or progressive angina according to the Braunwald Unstable Angina Classification and the Canadian Cardiovascular Society Angina Classification.
Rehospitalisation due to unstable or progressive angina according to the Braunwald Unstable Angina Classification and the Canadian Cardiovascular Society Angina Classification.
Time frame: Day 30
Time to Coronary Artery Bypass Graft (CABG)
Time between the intervention and the Coronary Artery Bypass Graft (CABG)
Time frame: Day 30
Start is estimated for Dec 2022; primary completion for Dec 2023, 12 months later.
Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 12 months is below that.
Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione GISE Onlus